



Drug-Target Interaction Prediction for Drug Repurposing with Probabilistic Similarity Logic

SHOBEIR FAKHRAEI*
LOUIQA RASCHID
LISE GETOOR


University of Maryland, College Park, MD, USA



Outline

- Drug Repurposing
- Drug-Target Interaction Network
- Probabilistic Similarity Logic (PSL)
- Drug-Target Interaction Prediction with PSL
- Experimental Results

New Drug Development




- Time Consuming: New drugs take a decade to reach market.
- Costly: Development cost reaches 2 billion US dollars.



**Valley of death:
Most novel drug candidates
never get approved!**

Drugs

- Drugs:
Organic small molecules that bind to bio-molecular targets to activate/inhibit their functions
- Drug often affect multiple targets.
- Poly-pharmacology is an area of growing interest



Drug Repurposing

- Drug Affecting Multiple Targets:
 - Adverse side-effects
 - Unexpected therapeutic effect ←
- Drug Repurposing/Repositioning:
Finding new uses for approved drugs.
- No need for tests required for a new therapeutic compound
(Already approved)





Sildenafil was originally developed for pulmonary arterial hypertension

Need for Systematic Search


- Most new treatment are discovered by chance during clinical trials.
- There is a need for a better systematic approach.
- Experimental identification of drug-target associations is labor intensive and costly
- A better solution?






**Using computational predictions
to focus biological search**


Drug-Target Interaction Network




Drug-Target Interaction Network + Similarities




Multiple Similarities



D-T Interaction Network + Multiple Similarities





Drug-Target Interaction Prediction



- Data:
 - Drug-target interaction network
 - Set of drug-drug similarities
 - Set of target-target similarities
- Task:
 - Link Prediction (New drug-target interactions)

Challenges

- Data is not originally flat:
 - Classifiers need a set of features and instances.
 - Instances: all interactions in the network (pairwise) or only interaction of one drug or target.
 - Features: Feature engineering
- Not Independent and Identically Distributed (IID): Interactions depend on each other (a drug tends to interact with similar targets)
- Multi-relational:
 - Drug-Target Interactions
 - Different Drug-Drug Similarities
 - Different Target-Target Similarities






Probabilistic
Similarity
Logic

Probabilistic Similarity Logic


Probabilistic Similarity Logic (PSL)

- Declarative language based on logic to express collective probabilistic inference problems.
 - Logical foundation
 - Probabilistic foundation
 - Weight Learning



Logic Foundation

General Rules





e.g., $Interacts(D, T_2) \wedge SimilarTarget(T_1, T_2) \rightarrow Interacts(D, T_1)$

- Can use predicate to define relations between variables.
e.g. $Interacts(D, T)$
- Grounding: Instantiation of predicates with data.
e.g. $Interacts(acetaminophen, cox2)$
- Groundings have a soft-truth values between $[0, 1]$

Lukasiewicz t-norm and co-norm

$$P(A, B) \circledast Q(B, C) \rightarrow R(A, C)$$



- $P \tilde{\wedge} Q = \max(0, P + Q - 1)$
- $P \tilde{\vee} Q = \min(1, P + Q)$
- $\neg P = 1 - P$


Satisfaction

- Interpretation (I) : an assignment of soft-truth values to a set of groundings.
- Rule satisfaction: $r_{\text{body}} \rightarrow r_{\text{head}}$ is satisfied when $I(r_{\text{body}}) \leq I(r_{\text{head}})$

$$\begin{array}{c} \text{max}(0, 0.7 + 0.8 - 1) = 0.5 \\ \hline \begin{array}{ccc} \underbrace{\quad\quad\quad}_{0.7} & \underbrace{\quad\quad\quad}_{0.8} & \\ P(A, B) \wedge Q(B, C) & \rightarrow & R(A, C) \end{array} \\ \hline \underbrace{\hspace{10em}}_{\geq 0.5} \end{array}$$

Distance to Satisfaction

$$d_r(I) = \max(I(r_{body}) - I(r_{head}), 0)$$



Rule Weights

$$w : P(A, B) \wedge Q(B, C) \rightarrow R(A, C)$$

- Rule can have weights which corresponds to importance of the rule.
 - Can come from domain knowledge
 - Can be learned from data


Review

- PSL program + Dataset → Set of ground rules
- Some groundings (predicates) have known truth values and some have unknown truth values.
- Every Interpretation of unknown groundings (predicates) → different weighted distances to satisfaction
- How to decide which Interpretation is best?




Probabilistic Foundation

Probabilistic Model



Inferring Most Probable Explanations

- Given a set of observed groundings infer the values of unknown groundings
- e.g., Given a set of drug-target interactions + a set of D-D and T-T similarities infer the value of other interactions.
- Convex optimization: perform inference using the alternating direction method of multipliers (ADMM) [Bach et al., NIPS 2012]
- Fast, scalable, and straightforward
- Optimize sub-problems (ground rules) independently.






Weight Learning

Weight Learning

$$w : P(A, B) \wedge Q(B, C) \rightarrow R(A, C)$$

- Learn the weights from training data
- Various methods:
 - Approximate maximum likelihood [Broecheler et al., UAI 10]
 - Maximum pseudo-likelihood
 - Large-margin estimation



PSL Summary

- Design probabilistic models using declarative language
 - Syntax based on **first-order logic**
- Inference of most-probable explanation is fast **convex optimization** (ADMM)
- Learning algorithms for training rule weights from labeled data.



Drug-Target Interaction Prediction with PSL

Predicates


- $\text{Interacts}(D, T)$
- $\text{SimilarTarget}_\beta(T_1, T_2)$
 - e.g. β can be Sequence-based, PPI-network-based, Gene Ontology-based.
- $\text{SimilarDrug}_\alpha(D_1, D_2)$
 - e.g. α can be Chemical-based, Ligand-based, Expression-based, Side-effect-based, Annotation-based.



Drug-Target Interaction Prediction Rules


Triad-based rules (Targets)

- Drugs tend to interact with similar targets
(friend of friend is a friend)




Triad-based rules (Drugs)

- Targets tend to interact with similar drugs
(friend of friend is a friend)




Tetrad-based Rules (Similar Edges)

- Similar edges are likely to form in a graph



Negative Prior

- Negative prior indicates “Interacts” predicate is most likely false
- i.e., most drugs and targets do not interact



$$\neg \text{Interacts}(D, T)$$

Size of the problem

- Total ground triad-based rules can be:

$$O\left(\underbrace{(|D| \times |T|)}_{\substack{\text{All possible} \\ \text{interactions}}} \times \underbrace{(|D| \times |\alpha|)}_{\substack{\text{Triads based on} \\ \text{drug similarities} \\ \text{for an interaction}}} + \underbrace{|T| \times |\beta|}_{\substack{\text{Triads based on} \\ \text{target similarities} \\ \text{for an interaction}}}\right)$$

Diagram illustrating the complexity of ground triad-based rules. The formula is $O((|D| \times |T|) \times (|D| \times |\alpha| + |T| \times |\beta|))$. Brackets and labels explain the components:

- All possible interactions:** $|D| \times |T|$ (Number of drugs $|D|$ and Number of targets $|T|$)
- Triads based on drug similarities for an interaction:** $|D| \times |\alpha|$ (Number of drugs $|D|$ and Number of drug similarities $|\alpha|$)
- Triads based on target similarities for an interaction:** $|T| \times |\beta|$ (Number of targets $|T|$ and Number of target similarities $|\beta|$)

- e.g., in our experiments it was **180M**
- For tetrad-based rules the situation is even worst!




Blocking

Blocking

- Limit some of the rules from being grounded
- Ignore some of the less significant similarities between drugs and between targets.


Same Threshold for All Similarities

- Fixed threshold either ignores most of the values in one similarity or includes most of the values from the other




A Threshold for Each Similarity

- Same problem for individual drug or target!



K-Nearest Neighbors-based

- Preserve the k-highest values in each similarity for each drug and each target and set the others to zero.






PSL Advantages

PSL Advantages

- PSL captures the original structure
- Collective Inference (No IID assumption): Results in global information propagation through the network.
- Inference based on Interpretable rules
- Class Imbalance: PSL can handle huge class-imbalance problems in link prediction problems.





Experimental Evaluation

Dataset

- 315 Drugs
- 250 Targets
- Interaction: [Knox et al. 2011]
 - 1,306 observed interactions
 - 78,750 possible interactions
- Similarities: [Perlman et al. 2011]
 - 3 target-target similarities
 - 5 drug-drug similarities

Drug-Drug Similarities [Perlman et al. 2011]

- **Chemical-based:**
 - Jaccard similarity of the SMILES fingerprints
- **Ligand-based:**
 - Jaccard similarity between protein receptor families extracted via matched ligands with drugs SMILES
- **Expression-based:**
 - Spearman correlation of gene expression responses to drugs using Connectivity Map.
- **Side-effect-based:**
 - Jaccard similarity between drugs side-effects from SIDER
- **Annotation-based:**
 - Semantic Similarity of Drugs based on the World Health Organization ATC classification system

Target-Target Similarities [Perlman et al. 2011]

- **Sequence-based:**
 - Smith-Waterman sequence alignment scores
- **Protein-protein interaction network-based:**
 - The distance in the protein-protein interactions network using all-pairs shortest path.
- **Gene ontology-based:**
 - Semantic similarity between Gene ontology annotations

Triad Rules

	Rule	AUROC
Drug-Drug Similarity	Annotation-based	0.685 \pm 0.026
	Chemical-based	0.714 \pm 0.030
	Ligand-based	0.751 \pm 0.030
	Expression-based	0.584 \pm 0.025
	Side-effect-based	0.614 \pm 0.030
Target-Target Similarity	PPI-network-based	0.816 \pm 0.026
	GO-based	0.608 \pm 0.029
	Sequence-based	0.842 \pm 0.019
All rules (similarities)		0.931 \pm 0.018

Triad Rules:

Comparison with reported results

Method	AUROC	Condition
PSL	0.931 ± 0.018	Without Sampling (10 Fold C.V.)
Perlman et al. 2011	0.935	With Sampling (Reported Results)
Yamanishi et al. 2008	0.884	
Bleakley et al. 2009	0.814	


Triad Rules: Blocking and Weight Learning

Condition	AUROC		
	K=5	K=15	K=30
All weights fixed	0.926 \pm 0.016	0.929 \pm 0.020	0.923 \pm 0.021
+ Weight learning	0.930 \pm 0.016	0.931 \pm 0.018	0.924 \pm 0.21

Condition	Time to Complete (10-folds)		
	K=5	K=15	K=30
All weights fixed	12 mins	3 h	9 h
+ Weight learning	1 h	10 h	28 h

Triad Rules:

Precision of Top 100 Predictions



Triad and Tetrad based rules

Method	AUROC with k=5
Triad-based Rules	0.930 \pm 0.016
Tetrad-based Rules	0.796 \pm 0.025
Triad-based & Tetrad-based	0.913 \pm 0.017

Conclusion

- Identified challenges of network-based drug-target interaction prediction.
- Described PSL framework to address them:
 - Captures original network structure
 - Is a declarative language to implement different rules
 - Performs collective inference (No IID assumption)
 - Weight learning based on training data
- Matched performance of the state-of-the-art with simple triad-based rules.
- The proposed method can easily be applied to other tasks with similar structures.

Thank you

Drug-Target Interaction Prediction for Drug Repurposing with Probabilistic Similarity Logic

Shobeir Fakhraei*, Louiqa Raschid, Lise Getoor
University of Maryland, College Park, MD, USA

<http://psl.cs.umd.edu>



References

- L. Perlman, A. Gottlieb, N. Atias, E. Ruppin, and R. Sharan. “Combining Drug and Gene Similarity Measures for Drug-Target Elucidation.” *Journal of Computational Biology*, Feb. 2011
- Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. “DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. ” *Nucleic Acids Res.* Jan 2011
- Y. Yamanishi, M. Araki, A. Gutteridge, W. Honda, and M. Kanehisa. “Prediction of drug target interaction networks from the integration of chemical and genomic spaces.” *Bioinformatics*, Jul 2008.
- K. Bleakley and Y. Yamanishi. “Supervised prediction of drug target interactions using bipartite local models.” *Bioinformatics*, Sep. 2009
- Stephen H. Bach, Bert Huang, Ben London, and Lise Getoor, Hinge-loss, “Markov Random Fields: Convex Inference for Structured Prediction”, *Uncertainty in Artificial Intelligence (UAI)* 2013
- Stephen H. Bach, Matthias Broecheler, Lise Getoor, and Dianne P. O’Leary, “Scaling MPE Inference for Constrained Continuous Markov Random Fields with Consensus Optimization”, *Advances in Neural Information Processing Systems (NIPS)* 2012